Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

BNTX Stock: Buy at the High?

By Jason Hawthorne - Dec 8, 2020 at 10:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's development of a gene-based vaccine should help investors get over a high stock price

Buying high and selling low sounds good if you know what is high and low, or when it will happen. Unfortunately, many investors wait around for low prices that never come. This short-sightedness can cause them to miss out on potential life-changing gains in stocks that go on to shape the future.

A stock chart pointing up and to the right

Image source: Getty Images

Anchored to the past

With a global pandemic and BioNTech ( BNTX -17.44% ) partnering with Pfizer ( PFE -4.50% ) on a successful vaccine, it's actually surprising that the stock is only up 225% this year. Still, the stock trades at an all-time high and optimism for a vaccine -- the pair's vaccine was recently approved in the U.K. -- is palpable. Wary investors may be asking themselves if it wouldn't be better to sit back and try to buy shares at a lower price.

That makes sense. Our brains are conditioned to anchor on information we receive first. The thinking goes, if we buy it now we must be paying too much. Rather than deciding if the company's prospects warrant the current valuation, we compare the price now to the ones we've seen in the past. But let's consider that potential future.

Look to the future

The BioNTech-Pfizer vaccine will soon start filling syringes and arms around the developed world. The company -- along with Moderna ( MRNA -15.12% ) -- has validated an entirely new approach to developing vaccines. Using messenger RNA, the vaccine essentially turns our cells into machines that spur our immune system to pre-emptively fight, and later recognize, parts of the virus. The success of this vaccine represents a revolution in medicine, and Wall Street is typically quick to recognize companies that are transforming an industry. Investors would be wise not to let share price get in the way of owning a piece of that future.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$284.07 (-17.44%) $-59.99
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.83 (-4.50%) $-2.44
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$260.33 (-15.12%) $-46.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.